uniQure (NASDAQ:QURE - Get Free Report)'s stock price gapped down prior to trading on Tuesday . The stock had previously closed at $14.53, but opened at $14.07. uniQure shares last traded at $13.83, with a volume of 60,923 shares trading hands.
Analyst Upgrades and Downgrades
Several analysts have recently weighed in on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $70.00 target price on shares of uniQure in a report on Tuesday, March 4th. StockNews.com upgraded uniQure to a "sell" rating in a research report on Tuesday, March 11th. The Goldman Sachs Group raised their price target on uniQure from $9.00 to $20.00 and gave the company a "neutral" rating in a report on Thursday, December 12th. Guggenheim reaffirmed a "buy" rating on shares of uniQure in a report on Wednesday, December 11th. Finally, Leerink Partners increased their price objective on uniQure from $26.00 to $44.00 and gave the stock an "outperform" rating in a research report on Wednesday, December 11th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $38.89.
Check Out Our Latest Stock Analysis on uniQure
uniQure Stock Down 1.7 %
The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92. The stock has a 50 day moving average of $13.78 and a 200 day moving average of $10.50. The firm has a market capitalization of $740.85 million, a price-to-earnings ratio of -2.76 and a beta of 0.36.
Insider Buying and Selling at uniQure
In related news, CEO Matthew C. Kapusta sold 6,717 shares of the company's stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $11.32, for a total transaction of $76,036.44. Following the transaction, the chief executive officer now directly owns 580,795 shares of the company's stock, valued at approximately $6,574,599.40. The trade was a 1.14 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Christian Klemt sold 14,341 shares of the firm's stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $10.70, for a total value of $153,448.70. Following the sale, the chief financial officer now owns 152,372 shares of the company's stock, valued at $1,630,380.40. The trade was a 8.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 90,830 shares of company stock valued at $961,401. 4.74% of the stock is owned by insiders.
Institutional Investors Weigh In On uniQure
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in QURE. Avoro Capital Advisors LLC bought a new position in shares of uniQure during the 4th quarter valued at $38,410,000. Franklin Resources Inc. bought a new position in shares of uniQure during the 3rd quarter valued at $7,360,000. RTW Investments LP raised its holdings in shares of uniQure by 8,936.3% during the 4th quarter. RTW Investments LP now owns 903,625 shares of the biotechnology company's stock valued at $15,958,000 after purchasing an additional 893,625 shares in the last quarter. Point72 Asset Management L.P. raised its holdings in shares of uniQure by 81.3% during the 4th quarter. Point72 Asset Management L.P. now owns 1,771,352 shares of the biotechnology company's stock valued at $31,282,000 after purchasing an additional 794,459 shares in the last quarter. Finally, Boxer Capital Management LLC bought a new position in shares of uniQure during the 4th quarter valued at $13,245,000. Hedge funds and other institutional investors own 78.83% of the company's stock.
About uniQure
(
Get Free Report)
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.
Featured Articles
Before you consider uniQure, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and uniQure wasn't on the list.
While uniQure currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
